Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVersys AGXSWX:BIOV -1.85%4 EPS without NRI is CHF-3.92 as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 1,168 Biotechnology companies, BioVersys AG ranks worse than 85616.35% on this metric.
BioVersys AG's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was CHF-1.88.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.92.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BioVersys AG's EPS without NRI or its related term are showing as below:
XSWX:BIOV's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.4 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BioVersys AG's EPS (Diluted) for the
six
months ended in Dec. 2025 was CHF-1.84.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.89.
BioVersys AG's EPS (Basic) for the
six
months ended in Dec. 2025 was CHF-1.84.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.89.
BioVersys AG (XSWX:BIOV) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BioVersys AG EPS without NRI Related Terms
BioVersys AG EPS without NRI Historical Data
* Premium members only.
The historical data trend for BioVersys AG's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG EPS without NRI Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
EPS without NRI
-3.24
-3.92
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
EPS without NRI
-1.79
-1.45
-2.04
-1.88
XSWX:BIOV vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, BioVersys AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BioVersys AG's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-3.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (XSWX:BIOV) has a EPS without NRI of CHF-3.92 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #999999 out of 1168 companies in the Biotechnology industry.
Is BioVersys AG's EPS without NRI too high?
BioVersys AG's current EPS without NRI is CHF-3.92. Based on the distribution chart, BioVersys AG ranks #999999 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #999999 out of 1168 companies for EPS without NRI. This places BioVersys AG in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BioVersys AG and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current EPS without NRI is CHF-3.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current EPS without NRI of CHF-3.92. The current EPS without NRI is CHF-3.92. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current EPS without NRI is CHF-3.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 
